Intersect ENT Stock News

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?

Brokerages predict that Intersect ENT, Inc. (NASDAQ:XENT) will post ($0.35) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Intersect ENTs earnings. The lowest EPS estimate is ($0.42) and the highest is ($0.30). Intersect ENT posted earnings of ($0.54) per share during the same quarter []

Charles Schwab Investment Management Inc. boosted its stake in shares of Intersect ENT, Inc. (NASDAQ:XENT) by 3.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 228,097 shares of the medical equipment providers stock after buying an additional 7,912 shares during the quarter. []

Intersect ENT (NASDAQ:XENT) and Endologix (OTCMKTS:ELGXQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk. Profitability This table compares Intersect ENT and Endologixs net margins, return on equity and return on []

Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.

Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.

Northern Trust Corp reduced its stake in Intersect ENT, Inc. (NASDAQ:XENT) by 2.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 375,853 shares of the medical equipment providers stock after selling 8,274 shares during the period. Northern Trust Corps []

Intersect ENT (NASDAQ:XENT) and Soliton (NASDAQ:SOLY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Risk & Volatility Intersect ENT has a beta of 1.51, suggesting that its share price is []

Intersect ENT (NASDAQ:XENT) and Soliton (NASDAQ:SOLY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk. Risk and Volatility Intersect ENT has a beta of 1.51, suggesting that its share price is []

Wall Street analysts expect that Intersect ENT, Inc. (NASDAQ:XENT) will announce sales of $37.13 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Intersect ENTs earnings, with estimates ranging from $36.53 million to $37.82 million. Intersect ENT posted sales of $28.23 million in the same quarter last year, []

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class A

NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed acq

Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.

Medtronic plc (NYSE:MDT) announced it entered into a definitive agreement with Intersect ENT (NASDAQ: XENT) for $1.1 billion.  The post Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion ap